Astrocytic activation of EMMPRIN contributes to their pathological phenotype in ALS.
Gloria Nwamaka Edozie, Jasmine Bélanger, Shanna Pigeyre, Ariane Gosselin, Marion Boyer, Antoine G. Godin, Silvia Pozzi
The paper shows that EMMPRIN activation in astrocytes contributes to their pathological phenotype in ALS and suggests anti-EMMPRIN antibodies as a potential therapeutic approach.
bioRxiv · Feb 23, 2025 · PreprintNeuroscience